by the presence of a host cellular receptor. Here we use murine norovirus as a model to uncover an unappreciated connection between an intracellular lipid biosynthetic enzyme and a receptor conformation that is permissive for viral infection. The serine palmitoyltransferase complex is required for de novo sphingolipid biosynthesis and we find that its absence impairs the ability of murine norovirus to bind and enter cells. Although the serine palmitoyltransferase complex is dispensable for the surface expression of the norovirus receptor, CD300lf, serine palmitoyltransferase activity is required for CD300lf to adopt a conformation permissive for viral binding. Addition of extracellular ceramide to serine palmitoyltransferase-deficient cells chemically complements both the conformational changes of CD300lf and the cellular susceptibility to murine norovirus infection. Taken together, these data indicate that intracellular sphingolipid biosynthesis regulates the conformation of the murine norovirus receptor and therefore the tropism of murine norovirus. This indicates that intracellular biosynthetic pathways can regulate viral tropism even when the receptor for a virus is expressed on the target cell surface.
that the intracellular replication machinery for NoV is conserved across species. However, it remains unclear what additional cellular factors cooperate with proteinaceous receptors to enable NoV entry.
In our initial screen for genes required for MNoV replication we reported that two genes, Sptlc1 and Sptlc2, were important for MNoV replication 5 . Their encoded proteins are essential members of the serine palmitoyltransferase (SPT) complex, which catalyses the first and rate-limiting step in de novo ceramide and sphingolipid biosynthesis 11 . Ceramide and sphingolipids are important lipid mediators of membrane fluidity and dynamics 12, 13 . Ceramide can also function as a signalling lipid involved in cellular survival, metabolic homeostasis and inflammation [14] [15] [16] . However, the exact function of the SPT complex during NoV replication is unknown.
Here, we define a critical role for sphingolipid biosynthesis in MNoV infection and viral entry. Furthermore, we determine that the step in viral infection at which de novo sphingolipid biosynthesis is required is the binding of the virus to cells, a step also requiring the MNoV receptor CD300lf. Surprisingly, Sptlc2 deficiency did not lead to abnormal trafficking or localization of CD300lf, but altered the conformation of CD300lf so that it was not recognized by MNoV or a conformation dependent antibody. Chemical complementation of the Sptlc2-deficient cells altered the CD300lf conformation and restored MNoV susceptibility. Taken together, these data demonstrate that the lipid composition of host cells is a critical determinant of MNoV entry and that intracellular enzymes can regulate the conformation of viral receptors, providing an additional mechanism to regulate viral tropism.
The SPT complex consists of two proteins, Sptlc1 and Sptlc2. The Sptlc2 protein is the catalytic subunit whereas Sptlc1 is required for the stability of Sptlc2 in cells 11 . Therefore, we generated Sptlc2deficient BV2 cells (BV2Δ Sptlc2) using CRISPR-Cas9 technology ( Supplementary Figure 1) . We then tested the ability of MNoV strains that cause acute, systemic infection (MNoV CW3 ) or persistent, enteric infection (MNoV CR6 ) to replicate in Sptlc2-deficient cells. Whereas wild-type BV2 cells produced high titres of MNoV CW3 and MNoV CR6 strains of virus, BV2Δ Sptlc2 cells were deficient in MNoV production both after a single cycle (12 h) or multiple cycles (24 h) of replication ( Fig. 1a) . Importantly, the growth of both strains of MNoV was restored on expression of Sptlc2 cDNA (Fig. 1b) . A mutation that abolished Sptlc2 catalytic activity, Sptlc2 R507A , was unable to rescue MNoV replication in BV2Δ Sptlc2 cells, indicating that the SPT complex must be enzymatically active in order to support MNoV replication (Fig. 1b) 17 . Treatment of BV2 cells with myriocin, a potent inhibitor of the SPT enzyme, also reduced the number of MNoV infected cells ( Fig. 1c ).
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Having established a step in sphingolipid biosynthesis as required for efficient MNoV replication, we next identified the stage of the viral life cycle that is impaired in BV2Δ Sptlc2 cells. Equivalent levels of infectious virus were produced after transfection of MNoV CW3 viral RNA into wild type and BV2Δ Sptlc2 cells, indicating that sphingolipid biosynthesis is required for MNoV entry (Fig. 1d ). We then tested the ability of MNoV CW3 to bind to cells defective in sphingolipid biosynthesis. Wild-type BV2 cells had significantly enhanced binding compared to both BV2Δ CD300lf and BV2Δ Sptlc2 cells ( Fig. 1e ). This binding defect in BV2Δ Sptlc2 cells was rescued by expression of a wild-type Sptlc2 construct but not a catalytically inactive Sptlc2 (Fig. 1e ). These findings are consistent with a model in which Sptlc2 is required for efficient binding and entry of cells while post-entry replication of MNoV is not affected.
As CD300lf expression is essential for MNoV binding, we next tested the hypothesis that Sptlc2 is required for cell surface expression of this viral receptor. The amount of CD300lf on the surface of BV2Δ Sptlc2 cells was equivalent to wild type and complemented 
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NATure MiCrobiology cells as measured by flow cytometry and total CD300lf protein levels were equivalent as measured by western blot ( Fig. 2a-c ). Therefore, Sptlc2 deficiency does not alter the amount or the cell surface localization of the MNoV receptor. Because CD300lf can bind ceramide 18 , a lipid whose synthesis requires SPT activity, we wanted to test whether the conformation of CD300lf is altered in cells deficient in ceramide production. We found that the TX70 antibody recognizes CD300lf by flow cytometry but not by western blot analysis ( Fig. 2c and 3a, b ). Based on these observations, the recognition of CD300lf by TX70 is contextand, most probably, conformation-dependent and thus can be used as a tool to probe the configuration of CD300lf in sphingolipid and ceramide-deficient cells. To test this hypothesis we stably expressed a CD300lf construct with a C-terminal Flag-tag in both wild type and BV2Δ Sptlc2 cells ( Fig. 3a ). We used this approach because we were unable to detect endogenous CD300lf using TX70 in BV2 cells (data not shown). This approach also allowed us to stain for both total CD300lf, using intracellular staining for the flag epitope, and the amount of cell-surface-expressed CD300lf, using the TX70 conformation-sensitive antibody. Although both wild type and BV2Δ Sptlc2 cells had similar levels of intracellular staining of the flag epitope, the CD300lf conformational-dependent antibody was significantly impaired in its ability to recognize CD300lf in BV2Δ Sptlc2 cells (Fig. 3b, c) . Additionally, TX70 staining in BV2Δ Sptlc2 + CD300lf-Flag cells could be rescued by expression of Sptlc2, although the total expression of CD300lf-Flag in all cells in this experiment was lower than the previous experiment due to use of a different CD300lf-Flag construct in conjunction with the Sptlc2-complementation constructs ( Fig. 3d ). Additionally, treatment of BV2 CD300lf-Flag cells with myriocin, an SPT inhibitor, decreased the TX70 staining compared to vehicle control ( Fig. 3e , f). The defect in TX70 recognition of the CD300lf-Flag was not due to improper trafficking or localization as both cell surface biotinylation and fluorescence microscopy experiments demonstrated that CD300lf-Flag is at the cell surface ( Fig. 3g, h) . Taken together, these data suggest that Sptlc2 is dispensable for CD300lf surface expression, but is required for a specific CD300lf structural configuration that is jointly recognized by a conformational dependent antibody and MNoV.
Having established that genetic disruption of the SPT complex altered MNoV infection and changed the conformation of CD300lf at the cell surface, we tested the hypothesis that this effect is due to the lack of sphingolipids and thus examined whether we could chemically complement the genetic deficiency in BV2Δ Spltlc2 cells. We chose to use a synthetic, soluble ceramide, C2 ceramide, to deliver to cells due to the synthesis of ceramide requiring SPT activity and the solubility of the C2 ceramide, which can traverse the lipid bilayers of cells. Addition of C2 ceramide to BV2Δ Sptlc2 restored MNoV CW3 infectivity as measured by flow cytometry (Fig. 4a ). Treatment with C2 ceramide treatment also restored the ability of the conformation-specific antibody TX70 to recognize a CD300lf-Flag transgene in BV2Δ Sptlc2 cells ( Fig. 4b, c ). Taken together, our genetic and chemical data indicate an essential role for sphingolipid biosynthesis, which occurs intracellularly, in regulating the conformation of CD300lf, which probably contributes to MNoV binding and cellular tropism.
A key factor in determining the cells, tissues and species a virus can infect, is the ability of viral proteins to engage cellular receptors.
Here we demonstrate that the essential and rate-limiting enzyme for de novo ceramide and sphingolipid biosynthesis, SPT, is required for efficient MNoV entry and binding, at least in part through controlling the conformation of a protein receptor. As norovirus entry is a limiting factor for in vitro replication, these findings may have implications for the development of efficient HNoV culture systems 4 . Extensive efforts to identify cellular models that enable HNoV replication have focused on potential receptors including HBGAs; however, our data shows that intracellular factors may contribute to the susceptibility of cells to norovirus infection 19, 20 . As HBGAs alone are not sufficient to explain HNoV cellular tropism, it is tempting to speculate that unappreciated intracellular pathways that regulate HBGA accessibility, or the conformation of unidentified protein receptors, regulate HNoV tropism and underlie the difficulty in establishing robust and tractable HNoV cell culture systems.
Most investigations into the relationship between viral entry and sphingolipids have identified a direct interaction between viruses and host lipids or describe an endosomal escape mechanism leveraging the unique geometry of ceramide in lipid bilayers [21] [22] [23] . We now 
NATure MiCrobiology provide evidence to support a new model in which the intracellular production of sphingolipids is required for a functional conformation of a viral receptor. Our data indicates that CD300lf is expressed equivalently on the surface of wild type and Sptlc2-deficient cells ( Fig. 2a-c) . Importantly, we and others have previously demonstrated that even minimal surface expression of CD300lf renders cells susceptible to MNoV infection 5, 6 . Rather surprisingly, here we uncover an unappreciated connection between the conformation of CD300lf and sphingolipid production that is associated with recognition by both the virus for binding to cells and a conformation specific anti-receptor antibody. The molecular details underlying the Sptlc2-dependent conformation of CD300lf are currently unknown. We previously mapped the critical regions of MNoV receptor activity of CD300lf to the amino acids that compose the CD300lf lipid binding pocket (Nelson et al., manuscript in preparation and ref. 5 ). Taken together these findings suggest the possibility that ceramide, or a sphingolipid, controls the conformation of CD300lf through its interactions with this ligand binding pocket. However, our data does not exclude the possibility that sphingolipids interact specifically with the transmembrane domain, as observed for other proteins 24 . It is also possible that the ceramidedependent conformation of CD300lf is a function of ceramide and/or sphingolipid molecules regulating the formation of membrane microdomains, such as lipid rafts, which may facilitate CD300lf clustering or controlling interactions with additional proteins at the cell surface 25 .
Previous work has shown that post-translational modifications of viral receptors by intracellular enzymes can regulate cellular susceptibility 26, 27 . Here, however, we report an intracellular biosynthetic enzyme that alters the conformation of a cell surface viral receptor protein. More broadly, these findings suggest that the blockade in binding and establishing infection for certain viruses is not the absence of a receptor but an intracellular deficiency that renders the receptor non-permissive for viral engagement.
Methods
Cells. BV2 cells previously karyotyped and confirmed to replicate MNoV 5 and 293T cells (ATCC) were cultured in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum and 10 mM HEPES. Puromycin (2.5 µ g ml −1 ; Sigma Aldrich) and blasticidin (5 µ g ml −1 ; Invitrogen) were added as indicated.
BV2Δ CD300lf cells have been described previously 5 . BV2Δ Sptlc2 cells were generated at the Genome Engineering and iPSC Center at Washington University School of Medicine. BV2 cells were nucleofected with Cas9 and Sptlc2-specific sgRNA (GATATCTTCGAGATTTCTTGAGG). Cells were then single-cell sorted and genomic DNA was extracted. DNA was amplified 
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NATure MiCrobiology using forward (AGCATGGCCTCGGTGTTCCATTGGT) and reverse (AGTCAAAGCAATCCTCCTGCCTCAA) primers. Clones were screened for frameshifts by sequencing the target region with Illumina MiSeq at approximately 500× coverage ( Supplementary Fig. 1) . All cell lines were tested and verified to be free of mycoplasma contamination.
MNoV assays. MNoV CW3 (GenBank accession number EF014462.1) and MNoV CR6 (GenBank accession number JQ237823) were generated by transfecting MNoV cDNA clones into 293T cells as described previously 28 . For MNoV growth curves, 5 × 10 4 cells were infected in suspension with MNoV CW3 or MNoV CR6 at a MOI of 0.05 in a single well of a 96-well plate. Plates were frozen at − 80 °C at 0, 12 or 24 h post infection. Total cell lysate was used in subsequent plaque assays as previously described 29 . All infections were performed in triplicate in each of at least three independent experiments. Viral RNA from MNoV CW3 was extracted from cell-free viral preparations using TRIzol (Invitrogen) according to the manufacturer's instructions. Purified RNA, which includes both host and viral RNA, was plaqued to ensure complete inactivation of MNoV. Ten micrograms of this RNA was transfected into target cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Transfected cells were frozen 12 h later. Each condition was assayed in triplicate by plaque assays in three independent experiments.
MNoV CW3 binding assays were performed as previously described 5 . Briefly, MNoV CW3 binding to BV2 cells was performed for 1 h at 4 °C in 0.5 ml complete growth medium. BV2 cells were used at a final concentration of 2 × 10 6 cells ml −1 and MNoV CW3 was used at a final concentration of 2.5 × 10 6 PFU ml −1 . Cells were centrifuged at 500 g for 5 min at 4 °C to remove unbound virus. Cells were washed four times with 1.0 ml PBS. RNA was extracted with the ZR Viral RNA kit (Zymo Research) according to the manufacturer's instructions. Quantitative PCR was performed as described previously for MNoV and rps29 30 . Binding experiments were conducted in triplicate in each of at least three independent experiments and binding was normalized within an experiment to the ratio of MNoV to rps29.
Plasmids. Mouse Sptlc2 cDNA was obtained from TransOMIC (pCS6 BC003227) and subsequently subcloned into pCDH-MCS-T2A-Puro vector (System Biosciences). Sptlc2 R507A was generated through overlap extension PCR. Codon optimized CD300lf-Flag, described previously 5 , was subcloned into pCDH-MCS-T2A-Puro or synthesized into pCMV-CD300lf-Flag-P2A-Blast (VectorBuilder). For the pCMV-CD300lf-Flag-P2A-Blast, we routinely observe lower expression compared to the pCDH-CD300lf-T2A-Puromycin. All plasmid constructs were sequence verified.
Lentiviral transduction.
Lentivirus was generated by transfecting lentiviral vectors with a packaging vector (psPAX2) and a pseudo-typing vector (pCMV-VSV-G) into 293T cells using TransIT-LT1 (Mirus). Supernatants were collected 48 h post-transfection, filtered through a 0.45 μ m filter (Millipore) and added to the indicated BV2 cells. After 48 h, cells were selected with the appropriate antibiotic.
Antibodies, flow cytometry and western blotting. The following antibodies were used for flow cytometry or western blotting as indicated: rabbit anti-Sptlc2 (Proteintech), mouse anti-GAPDH-HRP (Sigma), rat anti-CD300lf-PE clone TX70 (BioLegend), armenian hamster anti-CD300lf clone 3F6 (Genentech), rat anti-Flag-PE (BioLegend), rat anti-Flag-APC (BioLegend) and mouse anti-VP1-FITC (A6.2 monoclonal antibody conjugated to FITC; ref. 9 ).
Cells were placed on ice, washed once with PBS and then lysed in cold RIPA Buffer (50 mM Tris pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% IGEPAL, 0.5% sodium deoxycholate and 0.1% SDS) with HALT protease and phosphastase inhibitor cocktail (Sigma). Lysates were clarified by centrifugation before resolving on SDS-PAGE Stain-Free gels (BioRad) and transferring to PVDF membranes. Where indicated, total protein was quantified and used for normalization using a ChemiDoc MP Imaging System (BioRad).
For fluorescence-activated cell sorting (FACS) analysis, cells were isolated and probed for extracellular CD300lf expression previous to being fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences). Cells were stained with indicated antibodies intracellularly. Cells were then washed and analysed on a FACSCalibur flow cytometer (BD). At least 20,000 events were collected per condition. Each experiment was performed in triplicate in each of three independent experiments.
Cell surface biotinylation. For cell surface biotinylation experiments, the
Pierce Cell Surface Protein Isolation Kit (ThermoFisher) was used following the manufacturer's guidelines. Briefly, 12 × 10 6 BV2 or BV2Δ Sptlc2 cells expressing CD300lf-flag were seeded overnight, washed and Sulfo-NHS-SS-Biotin was added to cells in PBS on ice for 30 min. The labelling reaction was quenched before collecting and lysing cells. A sample of the clarified lysate was kept for western blot analysis and the remainder was added to streptavidin columns for the isolation of biotinylated proteins.
Microscopy. BV2 or BV2Δ Sptlc2 cells expressing CD300lf-flag-eGFP were seeded overnight onto glass coverslips in six-well dishes. Cells were fixed, permeabilized with 0.5% Triton X-10 and stained with AlexaFluor555-Phalloidin (ThermoFisher). Coverslips were mounted onto slides with ProLong Gold Antifade with DAPI (ThermoFisher), which were imaged on a Zeiss LSM 880 Confocal Laser Scanning Microscope.
Chemical inhibitors and complementation. Myriocin was purchased from Sigma and dissolved in methanol at 1.25 mM. For inhibition studies, cells were seeded overnight and the following day the media were changed to contain either methanol or myriocin (25 µ M). Twenty-four hours later, cells were either processed for FACS (Figs. 3e and 4f) or infected with MNoV CW3 (Fig. 1c) at an MOI of 5. Cells were collected for FACS 16-18 h after infection and stained intracellularly for MNoV capsid production.
C2 ceramide (d18:1/2:0; Avanti Lipids) was resuspended in dimethylsulphoxide (DMSO). Cells were seeded overnight in a six-well plate (2 x 10 6 cells per well). Media were removed and cells were subsequently washed with PBS. For infection 
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NATure MiCrobiology assays, cells were incubated with either 500 µ M C2 ceramide or DMSO with 1 x 10 6 PFU in a total volume of 500 µ l complete media, at room temperature for one hour with gentle rocking. Media was removed, cells were washed with PBS and fresh media were added to the cells. After 16-18 h, cells were collected for FACS and stained intracellularly for MNoV capsid production. A similar experimental setup was used for chemical complementation of the conformational dependent antibody recognition, except no virus was added and cells were only incubated for 45 min at room temperature before washing.
Data availability. The data that support the findings of this study are available from the corresponding authors upon request.
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